Royal Bank of Canada
PDLI

Royal Bank of Canada’s PDL BioPharma, Inc. PDLI Stock Holding History

Royal Bank of Canada’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-100
Closed -$1K – 6481
2013
Q4 		$1K Hold
100
– – ﹤0.01% 5881
2013
Q3 		$1K Buy
+100
New +$804 ﹤0.01% 6042

Other funds holding PDLI

SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $46.3B AUM 43.9% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $688M AUM 63.4% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
WG
Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Royal Bank of Canada's PDLI Position: Q4 2020 in Review

Royal Bank of Canada sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 16,713 shares — an estimated $53K sold.

Royal Bank of Canada first reported a position in PDLI in Q2 2013 and held it in 30 quarters. The position peaked at $22.1M in Q2 2014. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

  • Royal Bank of Canada reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
  • Royal Bank of Canada sold 16,713 PDL BioPharma, Inc. shares in Q4 2020, an estimated $53K.
  • Royal Bank of Canada first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 30 quarters.
  • Royal Bank of Canada's PDL BioPharma, Inc. position peaked at $22.1M in Q2 2014.
  • 33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on Royal Bank of Canada's 13F filing for Q4 2020, filed 16 Feb 2021.